In 2008, an intravenous formulation of C1‐INH concentrate ([C1‐INH(IV)]; Cinryze®; Shire ViroPharma Biologics, Inc.; Lexington, MA, USA) became available for routine prophylaxis of HAE attacks (Cinryze PI, 2015). This evidence concerns the gene SERPING1 and hereditary angioedema.